DE   EN   ES   FR   IT   PT


medicalmeds.eu Medicines Histamine drug. Betagistin таб п / about 24 mg No. 30

Betagistin таб п / about 24 mg No. 30

Препарат Бетагистин таб п/о 24мг №30. ЗАО "Северная Звезда" Россия


Producer: CJSC Severnaya Zvezda Russia

Code of automatic telephone exchange: N07CA01

Release form: Firm dosage forms. Tablets.

Indications to use: Menyer's disease. Menyer's disease. Vomiting. Nausea. Decrease in hearing. Sonitus. Headache. Dizziness.


General characteristics. Structure:

Active agent - a betagistina dihydrochloride.
Excipients: cellulose microcrystallic; lactose (sugar milk); citric acid; silicon dioxide colloid (aerosil); talc; magnesium stearate; sodium lauryl sulfate; starch 1500 (prezhelatinizirovanny starch).
Description: 24 mg - white or almost white color, a ploskotsilindrichesky form, with a facet and risky.




Pharmacological properties:

Pharmacodynamics. Betagistin affects mainly histamine N1-and H3 receptors of an inner ear and vestibular nuclei of TsNS. By direct agonistic impact on H1 receptors of vessels of an inner ear, and also indirectly through impact on H3 receptors improves microcirculation and permeability of capillaries, normalizes endolymph pressure in a labyrinth and a snail. At the same time бетагистин increases a blood stream in a basilar artery. Has the expressed central effect, being H3 receptors inhibitor of kernels of a vestibular nerve. Improves conductivity in neurons of vestibular nuclei at the level of a brain trunk. Clinical manifestation of the specified properties is decrease in frequency and intensity of dizzinesses, reduction of a sonitus, improvement of hearing in case of its decrease.

Pharmacokinetics. Communication with proteins of plasma - low is absorbed quickly. The maximum concentration in a blood plasma in 3 hours. An elimination half-life in 3-4 hours. It is almost completely removed by kidneys in the form of a metabolite (2-peridiluksusny acid) within 24 hours.


Indications to use:

Treatment and prevention of vestibular dizziness of various origin;
- the syndromes including dizziness and a headache, a sonitus, the progressing decrease in hearing, nausea and vomiting;
- disease or Menyer's syndrome.


Route of administration and doses:

Inside, during food. Tablets of 8 mg: 1-2 tablets 3 times a day. Tablets of 16 mg: ½ - 1 tablet 3 times a day. Tablet of 24 mg: on 1 tablet 2 times a day. Improvement is usually noted already at the beginning of therapy, the stable therapeutic effect occurs after two weeks of treatment and can increase within several months of treatment. Prolonged treatment. Duration of administration of drug is selected individually;



Side effects:

Gastrointestinal frustration, emergence of hypersensitivity reactions from integuments (rash, an itch, urticaria), a Quincke's edema.


Interaction with other medicines:

Cases of interaction or incompatibility with other medicines are unknown.
Influence on ability to driving and other mechanisms. Betagistin does not possess sedation and does not influence ability to drive the car or to be engaged in the types of activity demanding speed of psychomotor reactions.


Contraindications:

Hypersensitivity to any of drug components, children up to 18 years (due to the lack of data), pregnancy and the period of a lactation (due to the lack of data);

With care:

- a peptic ulcer of a stomach or a 12-perstny gut (including in the anamnesis), a pheochromocytomabronchial asthma.

The specified patients should be observed regularly during treatment;
- pregnancy and period of a lactation. There are not enough data for assessment of influence of drug during pregnancy and a lactation. In this regard reception at pregnancy is not recommended. For the period of treatment it is necessary to stop breastfeeding.


Overdose:

Symptoms: nausea, vomiting, spasms. Treatment: gastric lavage, reception of absorbent carbon, symptomatic therapy.


Storage conditions:

List B. In the dry, protected from light place, at a temperature not above 25 °C. To store in the place unavailable to children. Period of validity: 5 years. Not to use after expiry date.


Issue conditions:

According to the recipe


Packaging:

Tablets of 24 mg On 10 tablets in a blister strip packaging from a film of polyvinyl chloride and printing aluminum foil. On 30 tablets in bank of light-protective glass either in bank polymeric or in a bottle polymeric. Each can or a bottle or 3 blister strip packagings together with the application instruction are placed in a pack from a cardboard.



Similar drugs


  • Сайт детского здоровья